Translational Biotechnology
portes grátis
Translational Biotechnology
A Journey from Laboratory to Clinics
Hasija, Yasha
Elsevier Science Publishing Co Inc
01/2021
452
Mole
Inglês
9780128219720
15 a 20 dias
1020
Descrição não disponível.
Section 1. Introduction to Translational BiotechnologySection 2. BiotherapeuticsSection 3. Pathway and Target DiscoverySection 4. Novel Therapeutic ModalitiesSection 5. Bioinformatics to BedsideSection 6. Systems Approach and Engineering BiologySection 7. Drug Discovery, Personalized and Precision MedicineSection 8. Socio-Economic Impact of Translational Biotechnology
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
?Acute myeloid leukemia; Adoptive cell transfer therapy; Advanced research infrastructure; Advanced technology platform; Amphiphile; Amyloid; Antibiotic resistance; Antibodies; Antibody engineering; Antibody phage display; Applications; Artemisinin; Artificial intelligence; Bi-specific antibodies; Bio-therapeutics; Bio-therapeutics in COVID-19; Biological therapeutics; Biologics; Biomarker; Biomedical; Biopharmaceuticals; Biosimilars; Biotechnology; Bispecific antibodies; CAR-T-cell therapy; Cancer immunotherapy; Cell-based immunotherapy; Challenges; Chloroquine; Coiled-coil; Computer-aided drug discovery; Core facility; DNA vaccines; Dark genome DNA; Data-driven clinical research; Drug discovery; Drug discovery platform; Drug repositioning; Dual targeting; Economic development; Electronic health records; Enzyme replacement therapy; Euclidean distance; Evidence-based medicine; Fecal microbiota transplant therapy; Fibril; Fmoc; Genomics; Health economy; Hepatocellular carcinoma; Human disease model system; Hybridoma technology; Hydrogel; IPSCs; Implementation; Integrative biology; Interactome; Intergenic sequences; Knowledge translation; LncRNA; MRNA vaccines; Malaria drugs; Medical service system; MiRNA; Microbiome-based therapy; Monoclonal antibodies; Multifunctional antibodies; Nano-based drugs; Natural compounds; Networks; Neurodegenerative disorders; Neurodevelopmental disorders; New TOPSIS approach; Noncoding RNA; Noncoding sequences; Nonexpressive sequences; Nucleic acid therapeutics; Opportunities; Organoids; Peptide; Phage therapy; Pharma; Pharmacodynamic biomarker; Pharmacogenomics; Pharmacokinetic-pharmacodynamic drug responses; Pharmacokinetic-pharmacodynamic modeling; Prebiotics; Precision medicine; Probiotics; Proteomics; RDNA; RTS,S; Research hub; Scientific platform; Shared research facilities; Shared research infrastructure; SiRNA; Small molecules; Stem cells; Synthetic biology
Section 1. Introduction to Translational BiotechnologySection 2. BiotherapeuticsSection 3. Pathway and Target DiscoverySection 4. Novel Therapeutic ModalitiesSection 5. Bioinformatics to BedsideSection 6. Systems Approach and Engineering BiologySection 7. Drug Discovery, Personalized and Precision MedicineSection 8. Socio-Economic Impact of Translational Biotechnology
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
?Acute myeloid leukemia; Adoptive cell transfer therapy; Advanced research infrastructure; Advanced technology platform; Amphiphile; Amyloid; Antibiotic resistance; Antibodies; Antibody engineering; Antibody phage display; Applications; Artemisinin; Artificial intelligence; Bi-specific antibodies; Bio-therapeutics; Bio-therapeutics in COVID-19; Biological therapeutics; Biologics; Biomarker; Biomedical; Biopharmaceuticals; Biosimilars; Biotechnology; Bispecific antibodies; CAR-T-cell therapy; Cancer immunotherapy; Cell-based immunotherapy; Challenges; Chloroquine; Coiled-coil; Computer-aided drug discovery; Core facility; DNA vaccines; Dark genome DNA; Data-driven clinical research; Drug discovery; Drug discovery platform; Drug repositioning; Dual targeting; Economic development; Electronic health records; Enzyme replacement therapy; Euclidean distance; Evidence-based medicine; Fecal microbiota transplant therapy; Fibril; Fmoc; Genomics; Health economy; Hepatocellular carcinoma; Human disease model system; Hybridoma technology; Hydrogel; IPSCs; Implementation; Integrative biology; Interactome; Intergenic sequences; Knowledge translation; LncRNA; MRNA vaccines; Malaria drugs; Medical service system; MiRNA; Microbiome-based therapy; Monoclonal antibodies; Multifunctional antibodies; Nano-based drugs; Natural compounds; Networks; Neurodegenerative disorders; Neurodevelopmental disorders; New TOPSIS approach; Noncoding RNA; Noncoding sequences; Nonexpressive sequences; Nucleic acid therapeutics; Opportunities; Organoids; Peptide; Phage therapy; Pharma; Pharmacodynamic biomarker; Pharmacogenomics; Pharmacokinetic-pharmacodynamic drug responses; Pharmacokinetic-pharmacodynamic modeling; Prebiotics; Precision medicine; Probiotics; Proteomics; RDNA; RTS,S; Research hub; Scientific platform; Shared research facilities; Shared research infrastructure; SiRNA; Small molecules; Stem cells; Synthetic biology
